Related Experiment Video
Updated: Aug 14, 2026

Optimized System for Cerebral Perfusion Monitoring in the Rat Stroke Model of Intraluminal Middle Cerebral Artery Occlusion
Published on: February 17, 2013
Immunohistochemical patterns of selective cellular vulnerability in human cerebral ischemia
1Department of Neurology, Massachusetts General Hospital, Boston.
Insights
Human cerebral ischemia selectively damages pyramidal neurons, identified by SMI-32 staining, while sparing other cell types. This pattern mirrors animal models and suggests a role for excitatory amino acids in stroke damage.
Area of Science:
- Neuroscience
- Neuropathology
- Cerebrovascular Diseases
Background:
- Cerebral ischemia causes neuronal damage, but human-specific cellular vulnerability patterns remain unclear.
- Experimental models show selective neuronal loss, yet direct human data is limited.
Purpose of the Study:
- To investigate cellular vulnerability in human cerebral ischemia using histochemical methods.
- To compare findings in human lesions with experimental animal models.
Main Methods:
- Analysis of post-mortem brain specimens from seven patients with ischemic lesions.
- Utilized histochemical staining for SMI-32 (neurofilaments), MAP-2 (cytoskeletal protein), parvalbumin (GABAergic interneurons), c-fos (immediate early gene), and GFAP (glial marker).
Main Results:
- SMI-32 staining was significantly depleted in pyramidal projection neurons in acute lesions, indicating selective vulnerability.
- Other markers like MAP-2 and parvalbumin were relatively preserved.
- Dystrophic axons and axonal retraction balls were observed around lesions.
- c-fos expression was enhanced, while GFAP showed dynamic changes based on lesion age.
- SMI-32 loss persisted in chronic lesions.
Conclusions:
- Human cerebral ischemia exhibits selective vulnerability of pyramidal neurons, consistent with animal models.
- These findings validate animal studies for human relevance and suggest excitatory amino acid involvement in pathogenesis.
Abstract:
Although specific patterns of cellular vulnerability have been identified in experimental models of cerebral ischemia, there is little data on the occurrence of similar abnormalities in human ischemia. We therefore used a variety of histochemical methods to define changes affecting specific classes of cells in post-mortem specimens from seven patients with hippocampal and neocortical ischemic lesions. In acute lesions, staining with SMI-32, an antibody directed against nonphosphorylated neurofilaments that labels pyramidal projection neurons, was prominently depleted even when conventional Nissl staining revealed only mild pyknosis. In contrast, staining for other markers such as microtubule-associated protein 2 (MAP-2), another cytoskeletal protein, or parvalbumin, a calcium-binding protein found in gamma-aminobutyric acid (GABA)-ergic interneurons, were relatively preserved. SMI-32 antibody also labeled dystrophic axons and axonal retraction balls in and around acute ischemic lesions. The pattern of differential changes in immunoreactivity was essentially the same in all acute ischemic injuries, including both diffuse lesions in the CA1 field (Sommer's sector) and discrete infarcts in CA1 and neocortex. In addition, immunoreactivity for the immediate early gene product c-fos was enhanced in and around the acute ischemic lesions that we studied. In some very acute lesions, immunoreactivity for glial fibrillary acidic protein (GFAP) was depleted in areas of severe ischemia and necrosis, but, as expected, GFAP immunoreactivity was increased in lesions more than a few days old. In contrast, the loss of SMI-32 immunoreactivity persisted in chronic lesions. These findings are consistent with those of experimental ischemia in animals and confirm the relevance of these studies for human cerebral ischemia. The pattern of selective changes also resembles that of injuries induced directly by excitatory amino acids, which may play a significant role in the pathogenesis of ischemic damage.
More Related Videos
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology

